Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
9.82B | 9.68B | 9.84B | 10.17B | 10.98B | 13.44B | Gross Profit |
7.42B | 7.37B | 7.30B | 7.90B | 8.87B | 11.64B | EBIT |
2.27B | 2.22B | 2.10B | 2.32B | 2.84B | 4.55B | EBITDA |
2.70B | 2.83B | 2.38B | 4.36B | 2.49B | 5.73B | Net Income Common Stockholders |
1.48B | 1.63B | 1.16B | 3.05B | 1.56B | 4.00B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.07B | 2.38B | 1.05B | 4.89B | 3.80B | 2.61B | Total Assets |
26.57B | 28.05B | 26.84B | 24.55B | 23.88B | 24.62B | Total Debt |
6.95B | 6.63B | 7.34B | 6.61B | 7.60B | 7.83B | Net Debt |
5.87B | 4.26B | 6.29B | 3.19B | 5.34B | 6.50B | Total Liabilities |
11.35B | 11.33B | 12.05B | 11.17B | 12.92B | 13.93B | Stockholders Equity |
15.21B | 16.72B | 14.80B | 13.39B | 10.96B | 10.69B |
Cash Flow | Free Cash Flow | ||||
2.30B | 2.52B | 1.24B | 1.14B | 3.35B | 3.68B | Operating Cash Flow |
2.58B | 2.88B | 1.55B | 1.38B | 3.64B | 4.23B | Investing Cash Flow |
-780.50M | -799.20M | -4.10B | 1.58B | -563.70M | -608.60M | Financing Cash Flow |
-266.90M | -683.50M | 149.30M | -1.76B | -2.09B | -5.27B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $155.70B | 26.43 | 105.67% | 3.23% | 15.59% | 56.99% | |
72 Outperform | $19.32B | 12.87 | 9.19% | ― | 1.25% | 26.10% | |
71 Outperform | $136.00B | 22.99 | 32.51% | 2.84% | 4.63% | 1144.01% | |
68 Neutral | $121.57B | 20.71 | 7.34% | 3.25% | -4.57% | 2.96% | |
63 Neutral | $97.58B | 17.96 | 31.99% | 5.09% | 4.62% | ― | |
63 Neutral | $82.21B | 21.11 | 22.26% | 3.86% | 4.17% | -29.96% | |
54 Neutral | $5.28B | 3.29 | -45.38% | 2.80% | 16.77% | -0.08% |
On May 12, 2025, Biogen Inc. completed the issuance and sale of $1.75 billion in senior unsecured notes, with varying maturities and interest rates, to retire its outstanding 4.050% Senior Notes due 2025. The company plans to use the proceeds, along with cash on hand, to manage its debt obligations and for general corporate purposes, potentially impacting its financial flexibility and market positioning.
The most recent analyst rating on (BIIB) stock is a Buy with a $316.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.